A | B | C | D | E | F | G | H | I | K | L | M | N | O | P | Q | R | S | T | V | W | X | Z

Zolpidem insomnia



Zolpidem modified-release in insomnia - NCBI

12.24.2017 | Natalie Lawman
Zolpidem insomnia
Zolpidem modified-release in insomnia - NCBI

Zolpidem modified-release (MR) is the first hypnotic agent to be marketed in an extended-release formulation. Zolpidem MR is a two-layered, biphasic release.

Roth et al (2006) conducted a worldwide, multicenter, double-blind, placebo-controlled, parallel-group study in 212 adult outpatients, aged 18–64 years, with primary insomnia (diagnosed using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition). The purpose of this study was to evaluate the efficacy and safety of zolpidem MR 12.5 mg. The duration of treatment was 21 days with 2 nights at the outset of the study and 2 nights at the end of the study consisting of single-blind placebo.

Zolpidem for insomnia - Rsner - 2013

9.21.2017 | Natalie Lawman
Zolpidem insomnia
Zolpidem for insomnia - Rsner - 2013

To determine the effectiveness of zolpidem for insomnia treatment in to compare zolpidem with other new-generation hypnotics in terms of.

Two review authors will assess the relevance and eligibility of studies independently. We will outline the process of study identification and its results as flow diagrams according to the PRISMA statement ( Moher 2009 ). We will assess the eligibility and relevance of trials on the basis of their abstracts retrieved from the electronic searches. For studies that appear to meet the inclusion criteria according to the abstract information, we will obtain full-text versions for closer inspection.

to determine the effectiveness of zolpidem for insomnia treatment in comparison with placebo and active comparators;

* The distinction between primary and secondary insomnia is considered in the inclusion criteria as it has important implications for treatment: while treatment of primary insomnia focusses on the improvement of sleep, therapy of secondary insomnia should eliminate the causative medical problem (and if treated successfully, the insomnia will disappear as well).

Total sleep time (TST) Next-day alertness Adverse events (AEs).

Parallel randomised controlled trials (RCTs), which compare zolpidem with either placebo or active control in its effectiveness to improve sleep and/or in their potential to cause adverse events, withdrawal symptoms or rebound insomnia.

Zolpidem Oral Spray (Zolpimist) for Insomnia The Medical Letter, Inc

8.20.2017 | Brooke Lawman
Zolpidem insomnia

Zolpidem oral spray (Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate (Ambien, and others), has been.

Clinical Pharmacology and Biopharmaceutics Review. US Food and Drug Administration. Available at www.accessdata.fda.gov/scripts/cder/drugsatfda. Zolpimist (zolpidem tartrate) oral spray. Center for Drug Evaluation and Research. Accessed February 10, 2012. 3.

Zolpidem oral spray ( Zolpimist – NovaDel/ECR), a new formulation of the oral hypnotic zolpidem tartrate ( Ambien, and others), has been approved by the FDA for short-term treatment of insomnia characterized by difficulty falling asleep.

Drugs for insomnia. Treat Guidel Med Lett 2009; 7:23. 2.

more Show References Hide References 1. RELATED DRUGS — Zolpidem, zaleplon ( Sonata, and others), and eszopiclone (Lunesta) are benzodiazepine receptor agonists; they are not benzodiazepines, but appear to bind. Edluar – a new sublingual formulation of zolpidem. Med Lett Drugs Ther 2010; 52:29.

Rapid-acting with a short half-life, it is available as an immediate-release (IR) tablet, a sublingual tablet (Edluar) 1 and an extended-release (ER) tablet (Ambien CR). ZOLPIDEM — Zolpidem is the most frequently prescribed hypnotic in the US. A new sublingual tablet recently approved for middle-of-the-night awakening (Intermezzo) will be reviewed in a future issue of The Medical Letter.

Zolpidem for insomnia. - NCBI

3.15.2017 | Brooke Lawman
Zolpidem insomnia

The imidazopyridine derivative zolpidem, which acts as a benzodiazepine (BZ) receptor agonist, is the most widely prescribed hypnotic drug in the US.

Generate a file for use with external citation management software.

Warning: The NCBI web site requires JavaScript to function. more.

This review addresses the neuroreceptor properties of zolpidem; clinical pharmacokinetics, pharmacodynamics and drug interactions; efficacy as a hypnotic; adverse effects; tolerance, dependence and withdrawal; relation to motor vehicle accidents and complex sleep behaviors; and new dosage forms.

Approved doses of zolpidem (10 mg for adults, 5 mg for the elderly) are consistently effective in reducing sleep latency and consequently increasing sleep duration in patients with insomnia. However, favorable effects on sleep maintenance are observed less consistently. Residual daytime effects are unlikely with recommended doses, and provided that at least 8 h elapse prior to arising. Hypnotic efficacy is maintained with repeated nightly use, and the risk of rebound insomnia is low. Dependence and abuse of zolpidem are no more likely to occur than with typical benzodiazepines. Newly available novel dosage forms of zolpidem have increased therapeutic options for patients with insomnia variants such as sleep maintenance insomnia and middle-of-the-night awakening.

National Center for Biotechnology Information, U.S. National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA.

Efficacy of zolpidem in insomnia

11.23.2017 | Natalie Lawman
Zolpidem insomnia

Eur Psychiatry. 1997;12 Suppl 1:5-14. Efficacy of zolpidem in insomnia. Priest R(1), Terzano M, Parrino L, Boyer P. Author information: (1)St Mary's Hospital.

Zolpidem maintained normal sleep physiology as demonstrated by the preservation of slow wave stages and no, or minimal, effects on sleep architecture after abrupt discontinuation. Assessment methods used have included objective and subjective measures of hypnotic efficacy for different treatment durations, with results confirming that 10 mg is superior to placebo. The hypnotic activity of zolpidem has been explored in different patient populations including normal volunteers, general practice outpatients and psychiatric out- or in-patients with varying sleep disorders; both transient and chronic. The efficacy of zolpidem, a non benzodiazepine hypnotic agent with a short elimination half life, was reviewed, analysing more than 50 international clinical trials published since 1986. Consequently, 10 mg is the recommended dose for the short-term treatment of insomnia in the non-elderly; in elderly patients 5 mg has been shown to be effective at inducing sleep whilst giving an optimum safety profile. Zolpidem was shown to be superior in most trials on sleep parameters such as total sleep time, sleep onset latency and nocturnal awakenings, but total REM sleep and REM latency were usually unmodified.

Generate a file for use with external citation management software.

National Library of Medicine 8600 Rockville Pike, Bethesda MD, 20894 USA. National Center for Biotechnology Information, U.S.

Warning: The NCBI web site requires JavaScript to function. more.